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Background
The identification of targets and new drugs to fight can-
cer is one the greatest challenges for Biotechnology
researchers. Not only humans, but also animals are
affected by this disease. It is estimated for example that
one in every 3-4 dogs will develop some type of cancer
during its lifetime, twice as much as the human being
[1,2]. DNA methylation is an important epigenetic
mechanism which control gene expression during cell
proliferation and differentiation. Deregulation of this
mechanism is one of the events which can contribute to
the development of cancer [3]. The identification of epi-
genetic drugs, which are molecules that can revert aber-
rant DNA methylation, is one of the main areas of
cancer research nowadays. In this regard, natural pro-
ducts are a rich source of possibilities to increase the
arsenal of epigenetic drugs [1]. This study aims to ana-
lyze the cytotoxicity effect of curcumin treatments in
DH82 canine histiocytic sarcoma cell line. This polyphe-
nol derived from Curcuma longa has emerged as a
potent multimodal cancer-preventing agent which mod-
ulates multiple cell signaling pathways and also been
described as an inhibitor of DNA methylation[4]. The
knowledge of the biological effects of these substances
can pinpoint targets for the development of epigenetic
drugs, with a positive impact for the treatment of canine
and human cancer.
Materials and methods
DH82 cells grew under 37°C and 5% CO2, DMEM med-
ium was supplemented with 10% Bovine Fetal Serum.
To estimate DH82 viability and curcumin cytotoxicity,
the MTT protocol was performed at a concentration of
2 × 105 cells/well cultured in 96 well plates. After each
treatment, the cells were incubated during four hours
with a 5 μg/mL MTT (3 - (4,5-dimethylthiazol-2-yl)
-2,5-diphenyltetrazolium bromide) solution. Lastly the
MTT salt conversion to formazan crystals was quanti-
fied by spectrophotometry.
A curcumin therapeutic dose curve was established at
24, 48 and 72 hours treatments.
Results and discussions
In 24 hours, the IC50 was 21.88µg/mL (59.4µM), in 48
hours was 14.26µg/mL (38.7µM) and in 72 hours was
12.17µg/mL (33.0µM). A range of values were obtained
and the dispersion, especially on IC50 coordinate coincides
with the trend line, showing good positive correlation.
Conclusions
The DH82 cell line demonstrated susceptibility to treat-
ments with curcumin, which reflects the importance of
this natural product as a tool for the development of new
epigenetic drugs which could be also explored to fight
cancer in pet dogs.
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